2011-2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France.
Aging
Oropharyngeal neoplasms
Papillomavirus infections
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
20 Sep 2022
20 Sep 2022
Historique:
received:
30
06
2022
accepted:
13
09
2022
entrez:
20
9
2022
pubmed:
21
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
The objective of our study was to investigate changes over the past decade in patient age and the prevalence of HPV in the population of patients with oropharyngeal carcinoma (OPC) treated at our center. We performed a retrospective cohort study of patients treated at our cancer center for OPC between 2011 and 2021. Tissue biopsies were assessed for HPV status based on p16 staining for all patients. There were 1,365 treated patients. The proportion of p16-positive patients increased from 43% in 2011 to 57.3% in 2021 (p = 0.01). The sex ratio was 3.6 M/1F for p16-positive and 3.7 M/1F for p16-negative patients (p = 0.94). The mean age increased from 60.2 y in 2011 to 63.6 y in 2021. The mean ages were 61.9 y for p16-positive and 61.7 y for p16-negative patients (p = 0.71), but there was a broader age distribution for the p16-positive patients (p = 0.03). The proportion of patients older than 70 y increased from 11% in 2011 to 28.2% in 2021, and this aging was similar between p16-positive (30.7% in 2021) and p16-negative (26.3% in 2021) patients. The 2-year and 5-year OS rates were 73.7% and 56.5% for the entire cohort. p16-positive patients had 2-year and 5-year OS rates of 86.8% and 77.4%, respectively, whereas p16-negative patients had 2-year and 5-year OS rates of 63.9% and 40.5%. Assessment of the change over the past decade in the population of patients with OPC at our center showed that HPV-positive OPC now appear to have overtaken HPV-negative cases in France, with 57.3% in 2021, and showed significant aging, with almost thirty percent of patients now older than 70 years. Those combined changes emphasize some of the challenges to be addressed in future OPC management.
Sections du résumé
BACKGROUND
BACKGROUND
The objective of our study was to investigate changes over the past decade in patient age and the prevalence of HPV in the population of patients with oropharyngeal carcinoma (OPC) treated at our center.
METHODS
METHODS
We performed a retrospective cohort study of patients treated at our cancer center for OPC between 2011 and 2021. Tissue biopsies were assessed for HPV status based on p16 staining for all patients.
RESULTS
RESULTS
There were 1,365 treated patients. The proportion of p16-positive patients increased from 43% in 2011 to 57.3% in 2021 (p = 0.01). The sex ratio was 3.6 M/1F for p16-positive and 3.7 M/1F for p16-negative patients (p = 0.94). The mean age increased from 60.2 y in 2011 to 63.6 y in 2021. The mean ages were 61.9 y for p16-positive and 61.7 y for p16-negative patients (p = 0.71), but there was a broader age distribution for the p16-positive patients (p = 0.03). The proportion of patients older than 70 y increased from 11% in 2011 to 28.2% in 2021, and this aging was similar between p16-positive (30.7% in 2021) and p16-negative (26.3% in 2021) patients. The 2-year and 5-year OS rates were 73.7% and 56.5% for the entire cohort. p16-positive patients had 2-year and 5-year OS rates of 86.8% and 77.4%, respectively, whereas p16-negative patients had 2-year and 5-year OS rates of 63.9% and 40.5%.
CONCLUSIONS
CONCLUSIONS
Assessment of the change over the past decade in the population of patients with OPC at our center showed that HPV-positive OPC now appear to have overtaken HPV-negative cases in France, with 57.3% in 2021, and showed significant aging, with almost thirty percent of patients now older than 70 years. Those combined changes emphasize some of the challenges to be addressed in future OPC management.
Identifiants
pubmed: 36127667
doi: 10.1186/s12885-022-10091-8
pii: 10.1186/s12885-022-10091-8
pmc: PMC9490895
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1000Informations de copyright
© 2022. The Author(s).
Références
J Clin Oncol. 2022 Jan 10;40(2):138-149
pubmed: 34699271
Int J Cancer. 2009 Jul 15;125(2):362-6
pubmed: 19330833
Cancer Prev Res (Phila). 2019 Jun;12(6):375-382
pubmed: 31003993
Radiother Oncol. 2022 Mar;168:40-45
pubmed: 35093406
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Oral Oncol. 2017 Apr;67:29-36
pubmed: 28351578
JAMA Otolaryngol Head Neck Surg. 2022 Jul 1;148(7):670-676
pubmed: 35587353
Eur J Cancer Prev. 2022 Mar 1;31(2):158-165
pubmed: 34267108
J Clin Oncol. 2018 Nov 1;36(31):3152-3161
pubmed: 30188786
Oral Oncol. 2021 Jan;112:105041
pubmed: 33129057
BMC Cancer. 2015 Aug 27;15:602
pubmed: 26311526
J Clin Oncol. 2020 Apr 1;38(10):1050-1058
pubmed: 32017652
PLoS One. 2018 Feb 7;13(2):e0192621
pubmed: 29415020
Oral Oncol. 2020 Aug 31;109:104687
pubmed: 32882642
Radiother Oncol. 2021 Apr;157:122-129
pubmed: 33545255
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Bull Cancer. 2010 Jan;97(1):47-54
pubmed: 19995688
Expert Rev Vaccines. 2020 Nov;19(11):1073-1083
pubmed: 33267673
Cancer. 2019 Dec 15;125(24):4407-4416
pubmed: 31454434
Cancer Epidemiol. 2019 Aug;61:89-94
pubmed: 31158796
Head Neck Pathol. 2012 Jul;6 Suppl 1:S16-24
pubmed: 22782220
Lancet Oncol. 2019 Oct;20(10):1349-1359
pubmed: 31416685
Lancet Glob Health. 2020 Feb;8(2):e180-e190
pubmed: 31862245
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
J Community Health. 2015 Jun;40(3):414-8
pubmed: 25301588
Cancer Res. 2016 Nov 15;76(22):6598-6606
pubmed: 27569214
Int J Cancer. 2014 Feb 1;134(3):497-507
pubmed: 23568556
Sci Rep. 2020 Aug 6;10(1):13219
pubmed: 32764593
Lancet Oncol. 2021 May;22(5):727-736
pubmed: 33862002
J Natl Compr Canc Netw. 2022 Mar;20(3):224-234
pubmed: 35276673